연구동향 분석

만성변비 치료의 최근 동향

홍경섭 ( Kyoung Sup Hong ) 정기욱 ( Kee Wook Jung ) 이태희 ( Tae Hee Lee ) 이봉은 ( Bong Eun Lee ) 박선영 ( Sun Young Park ) 신정은 ( Jeong Eun Shin ) 김성은 ( Seong Eun Kim ) 박경식 ( Kyung Sik Park ) 최석채 ( Suck Chei Choi ) 2014년

논문상세정보
인용/피인용
' 만성변비 치료의 최근 동향' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • constipation
  • linaclotide
  • lubiprostone
  • prucalopride
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
177 0

0.0%

' 만성변비 치료의 최근 동향' 의 참고문헌

  • The continuing importance of bile acids in liver and intestinal disease
    Hofmann AF Arch Intern Med 159 : 2647 ~ 2658 - [1999]
  • The association between prucalopride efficacy and constipation type
    Jadav AM Tech Coloproctol 17 : 555 ~ 559 - [2013]
  • The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph
    Chapman H Eur J Pharmacol 554 : 98 ~ 105 - [2007]
  • Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation
    Shin A Aliment Pharmacol Ther 39 : 239 ~ 253 - [2014]
  • Systematic review of randomised controlled trials: probiotics for functional constipation
    Chmielewska A World J Gastroenterol 16 : 69 ~ 75 - [2010]
  • Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C
    Vaandrager AB Mol Cell Biochem 230 : 73 ~ 83 - [2002]
  • Slow Transit Constipation Associated With Excess Methane Production and Its Improvement Following Rifaximin Therapy: A Case Report
    Uday C Ghoshal Journal of Neurogastroenterology and Motility (JNM) 17 (2) : 185 ~ 188 - [2011]
  • Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation
    Chey WD Aliment Pharmacol Ther 35 : 587 ~ 599 - [2012]
  • SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents
    Cuppoletti J Am J Physiol Cell Physiol 287 : C1173 ~ C1183 - [2004]
  • Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints
    Quigley EM Aliment Pharmacol Ther 37 : 49 ~ 61 - [2013]
  • Randomised clinical trial:macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in a controlled environment
    Cinca R Aliment Pharmacol Ther 37 : 876 ~ 886 - [2013]
  • Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives
    Tack J Gut 58 : 357 ~ 365 - [2009]
  • Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis
    Suares NC Am J Gastroenterol 106 : 1582 ~ 1591 - [2011]
  • Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses
    Shailubhai K Dig Dis Sci 58 : 2580 ~ 2586 - [2013]
  • Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery
    Delaney CP Dis Colon Rectum 48 : 1114 ~ 1125 - [2005]
  • Methylnaltrexone for opioid-induced constipation in advanced illness
    Thomas J N Engl J Med 358 : 2332 ~ 2343 - [2008]
  • Methanogens, Methane and Gastrointestinal Motility
    Konstantinos Triantafyllou Journal of Neurogastroenterology and Motility (JNM) 20 (1) : 31 ~ 40 - [2014]
  • Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS
    Attaluri A Am J Gastroenterol 105 : 1407 ~ 1411 [2010]
  • Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation
    Lembo AJ Dig Dis Sci 56 : 2639 ~ 2645 - [2011]
  • Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial
    Rao SS Am J Gastroenterol 105 : 890 ~ 896 - [2010]
  • Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population
    Migeon-Duballet I Curr Med Res Opin 22 : 1227 ~ 1235 - [2006]
  • Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase- C and extracellular cyclic guanosine 3',5'-monophosphate
    Castro J Gastroenterology 145 : 1334 ~ 1346 - [2013]
  • Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety
    Chey WD Am J Gastroenterol 107 : 1702 ~ 1712 - [2012]
  • Intestinal microbiota in functional bowel disorders: a Rome foundation report
    Simrén M Gut 62 : 159 ~ 176 - [2013]
  • Highly effective new oral therapy for faecal impaction
    Culbert P Br J Gen Pract 48 : 1599 ~ 1600 - [1998]
  • Evaluation of polyethylene glycol plus electrolytes in the treatment of severe constipation and faecal impaction in adults
    Chen CC Curr Med Res Opin 21 : 1595 ~ 1602 - [2005]
  • Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation
    Wong BS Am J Gastroenterol 106 : 2154 ~ 2164 - [2011]
  • Effect of prucalopride on symptoms of chronic constipation
    Tack J Neurogastroenterol Motil 26 : 21 ~ 27 - [2014]
  • Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon
    Chadwick VS J Lab Clin Med 94 : 661 ~ 674 - [1979]
  • Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis
    Ford AC Gut 60 : 209 ~ 218 - [2011]
  • Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers
    Camilleri M Am J Physiol Gastrointest Liver Physiol 290 : G942 ~ G947 - [2006]
  • Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome
    Andresen V Gastroenterology 133 : 761 ~ 768 - [2007]
  • Dyssynergic defecation and biofeedback therapy
    Rao SS Gastroenterol Clin North Am 37 : 569 ~ 586 - [2008]
  • Clinical trial:the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study
    Quigley EM Aliment Pharmacol Ther 29 : 315 ~ 328 - [2009]
  • Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation
    Johanson JF Aliment Pharmacol Ther 27 : 685 ~ 696 - [2008]
  • Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies
    Drossman DA Aliment Pharmacol Ther 29 : 329 ~ 341 - [2009]
  • Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study
    Büchler MW Aliment Pharmacol Ther 28 : 312 ~ 325 [2008]
  • Chronic constipation: a survey of the patient perspective
    Johanson JF Aliment Pharmacol Ther 25 : 599 ~ 608 - [2007]
  • Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit
    Tooth D Gut 63 : 753 ~ 760 - [2014]
  • Breath methane positivity is more common and higher in patients with objectively proven delayed transit constipation
    Lee KM Eur J Gastroenterol Hepatol 25 : 726 ~ 732 - [2013]
  • Biofeedback therapy for defecatory dysfunction: 'real life' experience
    Jodorkovsky D J Clin Gastroenterol 47 : 252 ~ 255 - [2013]
  • Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit
    Conley DR Am J Dig Dis 21 : 453 ~ 458 - [1976]
  • Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment- randomized clinical trial
    Paulson DM J Pain 6 : 184 ~ 192 - [2005]
  • Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study
    Viscusi ER Surg Endosc 20 : 64 ~ 70 - [2006]
  • A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain
    Cryer B Pain Med [2014]
  • A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation
    Chey WD Am J Gastroenterol 106 : 1803 ~ 1812 - [2011]
  • A placebo-controlled trial of prucalopride for severe chronic constipation
    Camilleri M N Engl J Med 358 : 2344 ~ 2354 - [2008]
  • A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation
    Rao S Am J Gastroenterol 107 : 1714 ~ 1724 - [2012]